Monovalent rotavirus vaccine provides protection against an emerging fully heterotypic G9P[4] rotavirus strain in Mexico

J Infect Dis. 2011 Sep 1;204(5):783-6. doi: 10.1093/infdis/jir390. Epub 2011 Aug 2.

Abstract

After the introduction of monovalent rotavirus vaccine (RV1) in Mexico in 2006-2007, diarrhea mortality and morbidity declined substantially among Mexican children under 5 years of age. In January 2010, surveillance identified the emergence of a novel G9P[4] rotavirus strain nationwide. We conducted a case-control study to assess the field effectiveness of RV1 against severe rotavirus gastroenteritis caused by this unusual strain and to determine whether the G9P[4] emergence was related to vaccine failure or failure to vaccinate. RV1 was 94% effective (95% confidence interval, 16%-100%) against G9P[4] rotavirus-related hospitalization, indicating that its emergence was likely unrelated to vaccine pressure.

MeSH terms

  • Case-Control Studies
  • Female
  • Gastroenteritis / prevention & control*
  • Gastroenteritis / virology*
  • Humans
  • Infant
  • Male
  • Mexico / epidemiology
  • Rotavirus Infections / epidemiology*
  • Rotavirus Infections / prevention & control*
  • Rotavirus Infections / virology
  • Rotavirus Vaccines*
  • Rotavirus*

Substances

  • Rotavirus Vaccines